Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Diabetes Research and Clinical Practice

• Publication date

  2013-08-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0168-8227(13)70003-2PMID 23647715
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• RECOMMANDATIONS 2012 EN DIABÉTOLOGIE: Prise en charge de l'hyperglycémie dans le diabète de type 2: une approche centrée sur le patient

  2012cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cited by this paper
• Standards of Medical Care in Diabetes—2011

  2011cited by this paper
• A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations

  2011cited by this paper
• Diabetes Clinical Practice Guidelines (CPGs) for the ASEAN region: Country Initiatives for Collectively Enhanced Diabetes Care in the Region

  2011cited by this paper
• An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study.

  2011cited by this paper
• Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study.

  2010cited by this paper
• Early and Aggressive Initiation of Insulin Therapy for Type 2 Diabetes: What Is the Evidence?

  2009influential reference
• Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix® 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study

  2009cited by this paper
• Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study

  2008cited by this paper
• Biphasic Insulin Aspart in Type 2 Diabetes Mellitus

  2007cited by this paper
• Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

  2004cited by this paper
• Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes

  2003cited by this paper
• Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.

  2002cited by this paper
• Quality of life and diabetes

  1999cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper

• EuroQoL 5-Dimension Measures in Malaysia

  2021cites this paper
• Efficacy, Safety, and Quality of Treatment Satisfaction of Premixed Human and Analogue Insulin Regimens in a Large Cohort of Type 2 Diabetic Patients: PROGENS BENEFIT Observational Study

  2018cites this paper
• Review of insulin‐associated hypoglycemia and its impact on the management of diabetes in Southeast Asian countries

  2017cites this paper
• Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis

  2015cites this paper